重症COVID-19患者体外可见异常纤维蛋白凝块结构
该横断面观察研究纳入2020年7月1日至8月1日ICU收治的36例患者,其中26例为逆转录聚合酶链反应确诊的SARS-CoV-2感染,10例为无COVID-19的脓毒症患者。采集血小板贫乏血浆分析纤维蛋白凝块结构与功能,发现COVID-19患者荧光纤维蛋白面积百分比为48.1%(SD 16%)vs 无COVID-19脓毒症患者24.9%(SD 18.8%),p=0.049;最大浊度0.168 vs 0.089 OD单位,p=0.003;缓冲液流经时间216 vs 103分钟,p=0.003。COVID-19患者D-二聚体水平与荧光纤维蛋白面积百分比正相关(ρ=0.714,p=0.047)。更致密的凝块(经浊度和血栓弹力图评估)及更高的SOFA评分与凝块溶解延迟独立相关。
要点
- 重症COVID-19患者体外纤维蛋白凝块较无COVID-19脓毒症患者更致密:荧光纤维蛋白面积百分比48.1%(SD 16%)vs 24.9%(SD 18.8%),p=0.049。
- COVID-19患者凝块最大浊度更高(0.168 vs 0.089 OD单位,p=0.003),缓冲液流经时间更长(216 vs 103分钟,p=0.003)。
- COVID-19患者D-二聚体水平与荧光纤维蛋白面积百分比正相关(ρ=0.714,p=0.047)。
- 更致密的凝块(经浊度和血栓弹力图评估)及更高的SOFA评分与凝块溶解延迟独立相关。
- COVID-19患者接受抗凝治疗的比例更高(100% vs 70%,p=0.003)。
适用人群与场景
- 2020年7月1日至8月1日收入学术医疗中心ICU的患者,包括逆转录聚合酶链反应确诊SARS-CoV-2感染的重症患者,以及收入ICU的脓毒症患者。
- 共36例,其中COVID-19患者26例,无COVID-19的脓毒症患者10例;采血时间为入ICU后中位11天(四分位距3-16天)。
- 两组在年龄、性别、体重指数、合并症、序贯器官衰竭评估(SOFA)评分和死亡率方面相似。
研究设计与关键结果
- 研究类型为横断面观察研究;共纳入36例患者,包括26例ICU COVID-19患者和10例ICU无COVID-19的脓毒症患者;采血时间为入ICU后中位11天(四分位距3-16天)。
- COVID-19患者接受抗凝治疗的比例更高(100% vs 70%,p=0.003)。
- COVID-19患者体外形成的纤维蛋白凝块较无COVID-19脓毒症患者更致密、孔隙更小:荧光纤维蛋白面积百分比48.1%(SD 16%)vs 24.9%(SD 18.8%),p=0.049。
- 浊度及流经实验证实上述数据:COVID-19患者纤维蛋白凝块最大浊度高于无COVID-19患者(0.168 vs 0.089 OD单位,p=0.003),缓冲液流经凝块时间更长(216 vs 103分钟,p=0.003)。
- 在COVID-19患者中,D-二聚体水平与荧光纤维蛋白面积百分比正相关(ρ=0.714,p=0.047)。
- 更致密的凝块(经浊度和血栓弹力图评估)及更高的SOFA评分与凝块溶解延迟独立相关。
证据类型、等级与局限
- 证据类型:横断面观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,重症COVID-19患者存在异常的纤维蛋白凝块结构和功能,这些发现可能 contribute to COVID-19患者广泛纤维蛋白沉积所观察到的较差结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Disseminated fibrin-rich microthrombi have been reported in patients who died from COVID-19. Our objective is to determine whether the fibrin clot structure and function differ between critically ill patients with or without COVID-19 and to correlate the structure with clinical coagulation biomarkers.
DESIGN: A cross-sectional observational study. Platelet poor plasma was used to analyze fibrin clot structure; the functional implications were determined by quantifying clot turbidity and porosity.
SETTING: ICU at an academic medical center and an academic laboratory.
PATIENTS: Patients admitted from July 1 to August 1, 2020, to the ICU with severe acute respiratory syndrome coronavirus 2 infection confirmed by reverse transcription-polymerase chain reaction or patients admitted to the ICU with sepsis.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Blood was collected from 36 patients including 26 ICU patients with COVID-19 and 10 ICU patients with sepsis but without COVID-19 at a median of 11 days after ICU admission (interquartile range, 3-16). The cohorts were similar in age, gender, body mass index, comorbidities, Sequential Organ Failure Assessment (SOFA) score, and mortality. More patients with COVID-19 (100% vs 70%; p = 0.003) required anticoagulation. Ex vivo fibrin clots formed from patients with COVID-19 appeared to be denser and to have smaller pores than those from patients with sepsis but without COVID-19 (percent area of fluorescent fibrin 48.1% [SD, 16%] vs 24.9% [SD, 18.8%]; p = 0.049). The turbidity and flow-through assays corroborated these data; fibrin clots had a higher maximum turbidity in patients with COVID-19 compared with patients without COVID-19 (0.168 vs 0.089 OD units; p = 0.003), and it took longer for buffer to flow through these clots (216 vs 103 min; p = 0.003). In patients with COVID-19, d-dimer levels were positively correlated with percent area of fluorescent fibrin (ρ = 0.714, p = 0.047). Denser clots (assessed by turbidity and thromboelastography) and higher SOFA scores were independently associated with delayed clot lysis.
CONCLUSIONS: We found aberrant fibrin clot structure and function in critically ill patients with COVID-19. These findings may contribute to the poor outcomes observed in COVID-19 patients with widespread fibrin deposition.
参考来源
- Brubaker LS, Saini A, Nguyen TC, et al. Aberrant Fibrin Clot Structure Visualized Ex Vivo in Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Crit Care Med. 2022. PMID: 35170535. doi:10.1097/CCM.0000000000005465
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。